NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

MEOI and HRQoL in CLL Patients Treated With BTKis

CompletedN/A

Sponsor: AstraZeneca

Conditions: Chronic Lymphocytic Leukemia

Countries: United States

This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* ≥18 years old
* Physician-confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL)
* BTKi naïve patients who initiate acalabrutinib or ibrutinib treatment alone or in combination with an anti-CD20 mAb within 7 days (before or after) study enrollment\*. Both treatment naïve and relapsed/refractory CLL patients will be included.
* Provides informed consent
* Adequate English reading skills
* Able to access and use a computer, tablet, or smartphone to complete PROs

Exclusion Criteria:

* Use of BTKi any time prior to study enrollment.
* Currently receiving systemic treatment for another malignancy
* Currently enrolled in a clinical trial

Locations (16)

Fountain Valley, California, United States
Redlands, California, United States
Boca Raton, Florida, United States
Fort Lauderdale, Florida, United States
St. Petersburg, Florida, United States
Tallahassee, Florida, United States
Tamarac, Florida, United States
Tampa, Florida, United States
Savannah, Georgia, United States
Honolulu, Hawaii, United States
Jackson, Mississippi, United States
Berkeley Heights, New Jersey, United States
Amherst, New York, United States
Charlotte, North Carolina, United States
Philadelphia, Pennsylvania, United States
York, Pennsylvania, United States